FDA Delays MOLBREEVI Review to November 2026; Q1 Net Loss Widens, Company Seeks to Double Authorized Shares
Summary
Savara Inc. reported a wider Q1 net loss and increased cash burn, while the FDA extended the review of its key drug candidate, MOLBREEVI, to November 2026 due to a 'major amendment.' The company is also seeking to double its authorized shares, indicating a need for future dilutive capital raises.
Key Events
-
FDA Delays MOLBREEVI Review
The FDA extended the Biologics License Application (BLA) review period for MOLBREEVI by three months to November 22, 2026, citing a 'major amendment' from the company's responses to information requests. This is a significant regulatory delay for the company's lead drug candidate in the U.S.
-
Q1 Net Loss Widens and Cash Burn Increases
The net loss for Q1 2026 widened to $37.3 million from $26.6 million in Q1 2025. This was driven by a 22.1% increase in R&D expenses and a 68.4% increase in G&A expenses. Cash used in operating activities increased to $33.0 million in Q1 2026 from $27.2 million in Q1 2025.
-
Liquidity Decreases, Runway at ~6 Quarters
Total cash and short-term investments decreased from $235.7 million as of December 31, 2025, to $202.8 million as of March 31, 2026. At the current burn rate, this provides approximately 6 quarters of liquidity.
-
Seeking to Double Authorized Shares
The company is seeking shareholder approval to increase its authorized common stock from 300 million to 600 million shares. With 204.9 million shares outstanding, this represents a potential dilution of up to 146% if all new shares were issued, likely to support future capital raises.
Analysis
Savara Inc. faces a significant setback with the FDA extending the review period for its lead drug candidate, MOLBREEVI, by three months due to a 'major amendment.' This delay directly impacts the commercialization timeline and the company's ability to access substantial contingent funding from its Hercules loan and royalty agreement. Concurrently, the company reported a widening net loss and increased cash burn, while also seeking to double its authorized shares, signaling a need for significant future capital that could lead to substantial dilution for existing shareholders.
At the time of this filing, SVRA was trading at $5.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1B. The 52-week trading range was $1.89 to $7.01. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.